Jefferies Financial Group Lowers Safran (SAFRY) to Underperform

Share on StockTwits

Jefferies Financial Group cut shares of Safran (OTCMKTS:SAFRY) from a hold rating to an underperform rating in a report released on Wednesday morning, The Fly reports. Jefferies Financial Group also issued estimates for Safran’s FY2018 earnings at $1.35 EPS, FY2019 earnings at $1.74 EPS and FY2020 earnings at $2.18 EPS.

SAFRY has been the subject of a number of other research reports. Zacks Investment Research cut Safran from a buy rating to a hold rating in a report on Thursday, August 16th. Sanford C. Bernstein upgraded Safran from a market perform rating to an outperform rating in a report on Monday, September 10th. Finally, Deutsche Bank upgraded Safran from a hold rating to a buy rating in a report on Friday, September 7th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company. The company has an average rating of Hold.

Shares of OTCMKTS:SAFRY opened at $30.90 on Wednesday. The company has a debt-to-equity ratio of 0.39, a current ratio of 0.86 and a quick ratio of 0.59. Safran has a 1 year low of $24.82 and a 1 year high of $35.77. The stock has a market cap of $56.28 billion, a PE ratio of 17.46 and a beta of 0.74.

Safran Company Profile

Safran SA, together with its subsidiaries, engages in the aerospace and defense businesses worldwide. The company operates through three segments: Aerospace Propulsion, Aircraft Equipment, and Defense. The Aerospace Propulsion segment designs, develops, produces, and markets propulsion systems for commercial aircraft, military transport, training and combat aircraft, rocket engines, civil and military helicopters, and tactical missiles and drones.

Further Reading: How does inflation affect different investments?

The Fly

Receive News & Ratings for Safran Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Safran and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Roth Capital Boosts Ambarella  Price Target to $40.00
Roth Capital Boosts Ambarella Price Target to $40.00
AtriCure  Stock Rating Lowered by Zacks Investment Research
AtriCure Stock Rating Lowered by Zacks Investment Research
Cinemark  Rating Lowered to Hold at Zacks Investment Research
Cinemark Rating Lowered to Hold at Zacks Investment Research
American Business Bank  & Cr AGRICOLE S A/ADR  Head to Head Review
American Business Bank & Cr AGRICOLE S A/ADR Head to Head Review
CHINA RESOURES/ADR  versus Its Rivals Critical Review
CHINA RESOURES/ADR versus Its Rivals Critical Review
MedEquities Realty Trust Inc  Expected to Post Quarterly Sales of $13.95 Million
MedEquities Realty Trust Inc Expected to Post Quarterly Sales of $13.95 Million


© 2006-2018 Ticker Report